方法对比
并排查看您选择的方法；存在差异的行会高亮显示。
| 贝叶斯Ⅰ期临床试验× | 贝叶斯随机对照试验× | |
|---|---|---|
| 领域 | 流行病学 | 流行病学 |
| 方法族 | Process / pipeline | Process / pipeline |
| 起源年份≠ | 1990 | 1980s–2000s (formal methodology consolidated ~2004–2006) |
| 提出者≠ | O'Quigley, Pepe & Fisher (Continual Reassessment Method) | Donald A. Berry and David J. Spiegelhalter (applied Bayesian inference formally to RCT design) |
| 类型≠ | Adaptive Bayesian dose-finding design | Randomized experimental study with Bayesian inference |
| 开创性文献≠ | O'Quigley, J., Pepe, M., & Fisher, L. (1990). Continual reassessment method: a practical design for phase 1 clinical trials in cancer. Biometrics, 46(1), 33–48. DOI ↗ | Spiegelhalter, D. J., Abrams, K. R., & Myles, J. P. (2004). Bayesian Approaches to Clinical Trials and Health-Care Evaluation. Wiley. ISBN: 978-0471499756 |
| 别名 | Bayesian dose-finding trial, CRM trial, continual reassessment method trial, Bayesian dose-escalation study | Bayesian RCT, Bayesian adaptive trial, Bayesian clinical trial design, BRCT |
| 相关 | 5 | 5 |
| 摘要≠ | A Bayesian Phase I clinical trial uses prior probability models and sequential Bayes updating to find the maximum tolerated dose (MTD) of a new agent. Unlike the traditional 3+3 rule-based escalation, the Bayesian approach revises a dose-toxicity curve continuously as each patient's outcome is observed, allowing faster convergence to the true MTD while minimising exposure of patients to unsafe or subtherapeutic doses. | A Bayesian randomized clinical trial (Bayesian RCT) combines the rigour of random treatment allocation with Bayesian statistical inference, allowing researchers to incorporate prior evidence and update beliefs continuously as trial data accumulate. Unlike the classical frequentist RCT, it yields direct probability statements about treatment effects and supports pre-specified adaptive stopping rules based on posterior probabilities. |
| ScholarGate数据集 ↗ |
|
|